TY - JOUR
T1 - Involvement of intestinal efflux and metabolic instability in the pharmacokinetics of platycodin D in rats
AU - Kwon, Mihwa
AU - Ji, Hyeon Kyeong
AU - Goo, Soo Hyeon
AU - Nam, So Jeong
AU - Kang, Yun Ju
AU - Lee, Eunyoung
AU - Liu, Kwang Hyeon
AU - Choi, Min Koo
AU - Song, Im Sook
N1 - Publisher Copyright:
© 2017 The Japanese Society for the Study of Xenobiotics
PY - 2017/10
Y1 - 2017/10
N2 - We aimed to investigate the underlying mechanisms for low bioavailability of Platycodin D (PD) in rats. The bioavailability of PD was 1.89% with different half-lives depending on the administration route (2.14 ± 0.18 h for intravenous injection vs 5.42 ± 1.9 h for oral administration). The mean absorption time was 6.3 h calculated from the mean residence time of both administration routes. Consistent with these parameters, rat intestinal permeability using 3 different intestinal segments showed a low but greatest permeability in lower ileum (0.05 × 10−6 cm/s in jejunum and upper ileum vs 0.13 × 10−6 cm/s in lower ileum). The involvement of efflux system, probably Mrps, in upper ileum, could be explained from the efflux ratio of 6.4 and reduced efflux ratio by an Mrp inhibitor, MK571. The recovery of unchanged PD after the intravenous and oral administration was 50% and 5.2%, respectively, suggesting the contribution of gastrointestinal metabolism. In the gastrointestinal content, 4 metabolites of PD were identified: acetylated PD (m/z 1265.6), deglucose PD (m/z 1061.5), deapiose PD (m/z 1091.5), and deapiose-dexylose-derhamnose PD (m/z 813.4). In conclusion, the intestinal first-pass effect such as the presence of efflux functions in the upper ileum, limited but steady intestinal permeability, and gastrointestinal metabolism could explain the low bioavailability and prolonged absorption time of orally administered PD.
AB - We aimed to investigate the underlying mechanisms for low bioavailability of Platycodin D (PD) in rats. The bioavailability of PD was 1.89% with different half-lives depending on the administration route (2.14 ± 0.18 h for intravenous injection vs 5.42 ± 1.9 h for oral administration). The mean absorption time was 6.3 h calculated from the mean residence time of both administration routes. Consistent with these parameters, rat intestinal permeability using 3 different intestinal segments showed a low but greatest permeability in lower ileum (0.05 × 10−6 cm/s in jejunum and upper ileum vs 0.13 × 10−6 cm/s in lower ileum). The involvement of efflux system, probably Mrps, in upper ileum, could be explained from the efflux ratio of 6.4 and reduced efflux ratio by an Mrp inhibitor, MK571. The recovery of unchanged PD after the intravenous and oral administration was 50% and 5.2%, respectively, suggesting the contribution of gastrointestinal metabolism. In the gastrointestinal content, 4 metabolites of PD were identified: acetylated PD (m/z 1265.6), deglucose PD (m/z 1061.5), deapiose PD (m/z 1091.5), and deapiose-dexylose-derhamnose PD (m/z 813.4). In conclusion, the intestinal first-pass effect such as the presence of efflux functions in the upper ileum, limited but steady intestinal permeability, and gastrointestinal metabolism could explain the low bioavailability and prolonged absorption time of orally administered PD.
KW - Absorption time
KW - Gastrointestinal metabolism
KW - Intestinal first-pass effect
KW - Limited intestinal permeability
KW - Platycodin D (PD)
UR - http://www.scopus.com/inward/record.url?scp=85025090482&partnerID=8YFLogxK
U2 - 10.1016/j.dmpk.2017.05.005
DO - 10.1016/j.dmpk.2017.05.005
M3 - Article
C2 - 28743418
AN - SCOPUS:85025090482
SN - 1347-4367
VL - 32
SP - 248
EP - 254
JO - Drug Metabolism and Pharmacokinetics
JF - Drug Metabolism and Pharmacokinetics
IS - 5
ER -